Bibliographic Info
Recommendation
Recommended in favor
Conditional
Certainty of evidence
Low
(HIV adults and adolescents) dolutegravir (DTG) in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone is recommended as the preferred second-line regimen for children with approved dolutegravir (DTG) dosing for whom non-DTG-based regimens are failing
Also Featured In
This recommendation also appears in the following guidelines:
Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach